Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993280 | 1.00 | EGFR (0.42) | EGFRFBP1ESR1ESR2PDCD1 | |
| SCHEMBL14993283 | 1.00 | EGFR (0.42) | EGFRFBP1ESR1ESR2PDCD1 | |
| SCHEMBL9891035 | 0.89 | NPC1 (0.41) | FBP1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL6776338 | 0.79 | APP (0.37) | APPALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL13924679 | 0.78 | NPC1 (0.45) | FBP1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL566832 | 0.78 | NPC1 (0.45) | FBP1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL13232789 | 0.77 | FBP1 (0.50) | EGFRFBP1CA1CA2ALDH1A1 | |
| SCHEMBL5267615 | 0.76 | ALDH1A1 (0.49) | APPALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL9631799 | 0.76 | EGFR (0.47) | EGFRFBP1ESR1ESR2ALDH5A1 | |
| SCHEMBL6771097 | 0.75 | LOXL2 (0.41) | ABATCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270876-B1 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-12-22 | — | — | EP | claimed |
| CN-107427430-B | Nitrone inhibition of oxidation of unsaturated fats | 陶氏环球技术有限责任公司 | 2020-12-04 | — | — | CN | claimed |
| US-20200289392-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | US | claimed |
| EP-3644947-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | Dow Global Technologies LLC (US) | 2020-05-06 | — | — | EP | claimed |
| CN-110769808-A | Melanin production inhibitor composition | 陶氏环球技术有限责任公司 | 2020-02-07 | — | — | CN | claimed |
| EP-2785316-B1 | NITRONE COMPOUNDS FOR USE AS ANTIOXIDANT IN PERSONAL CARE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-06-19 | — | — | EP | claimed |
| EP-3270875-B1 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-05-01 | — | — | EP | claimed |
| WO-2019005437-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-01-03 | — | — | WO | claimed |
| US-10137071-B2 | Nitrone inhibition of oxidation of unsaturated fats | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-11-27 | — | — | US | claimed |
| US-10130574-B2 | Nitrone inhibition of oxidation of unsaturated fats | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-11-20 | — | — | US | claimed |
| EP-3270875-A1 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | Dow Global Technologies LLC (US) | 2018-01-24 | — | — | EP | claimed |
| WO-2016154018-A9 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-10-05 | — | — | WO | claimed |
| WO-2016154018-A1 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-29 | — | — | WO | claimed |
| WO-2016154022-A1 | NITRONE INHIBITION OF OXIDATION OF UNSATURATED FATS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-29 | — | — | WO | claimed |
| US-9452119-B2 | Nitrone compounds and their use in personal care | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-27 | — | — | US | claimed |
| US-9452118-B2 | Nitrone compounds and their use in personal care | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-27 | — | — | US | claimed |
| US-20150335546-A1 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | DOW GLOBAL TECHNOLOGIES LLC | 2015-11-26 | — | — | US | claimed |
| US-20140303255-A1 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | DOW GLOBAL TECHNOLOGIES LLC | 2014-10-09 | — | — | US | claimed |
| EP-2785316-A2 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | ANGUS Chemical Company (US) | 2014-10-08 | — | — | EP | claimed |
| WO-2013081778-A2 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | ANGUS CHEMICAL COMPANY (US) | 2013-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303255-A1 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | NOX1, NOX5, NOS1 | EGFR 1692/4885FBP1 3003/4885ESR1 1207/4885 |
| US-10130574-B2 | Nitrone inhibition of oxidation of unsaturated fats | FASN, TXNRD2, NOS1 | EGFR 4826/4885FBP1 1471/4885ESR1 1225/4885 |
| US-10137071-B2 | Nitrone inhibition of oxidation of unsaturated fats | FASN, NDUFB1, FADS1 | EGFR 4804/4885FBP1 1125/4885ESR1 1098/4885 |
| US-20150335546-A1 | NITRONE COMPOUNDS AND THEIR USE IN PERSONAL CARE | NOX1, NOX5, NOS1 | EGFR 1692/4885FBP1 3003/4885ESR1 1207/4885 |
| US-20200289392-A1 | A MELANOGENESIS INHIBITOR COMPOSITION | TYR, MC1R, MITF | EGFR 2025/4885FBP1 4720/4885ESR1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.